{"id":364087,"date":"2025-08-31T11:46:30","date_gmt":"2025-08-31T11:46:30","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-agios-pharmaceuticals\/"},"modified":"2025-08-31T11:46:31","modified_gmt":"2025-08-31T11:46:31","slug":"how-to-buy-agios-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/","title":{"rendered":"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Agios Pharmaceuticals, Inc. (AGIO) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-364087","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r - AGIO Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r - AGIO Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Agios Pharmaceuticals (AGIO) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Agios Pharmaceuticals (AGIO) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile \u00f6\u011frenin."},"intro":"Nadir hastal\u0131k tedavisinde devrim yaratabilecek bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Agios Pharmaceuticals (AGIO), h\u00fccresel metabolizma ara\u015ft\u0131rmalar\u0131nda \u00f6nc\u00fc konumda olup, hem \u00f6nemli b\u00fcy\u00fcme potansiyeli hem de klasik biyoteknoloji volatilitesi sunmaktad\u0131r. Bu sadece ba\u015fka bir hisse senedi de\u011fil\u2014t\u0131bbi inovasyona kat\u0131lma ve portf\u00f6y\u00fcn\u00fcz\u00fc b\u00fcy\u00fctme \u015fans\u0131d\u0131r. AGIO'yu benzersiz k\u0131lan \u00f6zellikleri ve stratejik olarak nas\u0131l konumlanabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Nadir hastal\u0131k tedavisinde devrim yaratabilecek bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Agios Pharmaceuticals (AGIO), h\u00fccresel metabolizma ara\u015ft\u0131rmalar\u0131nda \u00f6nc\u00fc konumda olup, hem \u00f6nemli b\u00fcy\u00fcme potansiyeli hem de klasik biyoteknoloji volatilitesi sunmaktad\u0131r. Bu sadece ba\u015fka bir hisse senedi de\u011fil\u2014t\u0131bbi inovasyona kat\u0131lma ve portf\u00f6y\u00fcn\u00fcz\u00fc b\u00fcy\u00fctme \u015fans\u0131d\u0131r. AGIO'yu benzersiz k\u0131lan \u00f6zellikleri ve stratejik olarak nas\u0131l konumlanabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 AGIO Hisse Senedi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>31 A\u011fustos 2025 itibar\u0131yla, Agios Pharmaceuticals (AGIO) NASDAQ'ta <strong>37,01 $<\/strong> seviyesinde i\u015flem g\u00f6rmektedir. Ancak as\u0131l \u00f6nemli olan \u015fu\u2014<strong>7 Eyl\u00fcl 2025<\/strong> bu hisse i\u00e7in kritik g\u00fcn. FDA'n\u0131n talasemi tedavisi i\u00e7in PYRUKYND onay\u0131n\u0131 verip vermeyece\u011fine karar verece\u011fi tarih, potansiyel olarak 1,2 milyar dolarl\u0131k bir pazar f\u0131rsat\u0131n\u0131 a\u00e7abilir.<\/p> <h3>B\u00fcy\u00fck Haberlerin Tarihsel Fiyat Tepkileri<\/h3> <p>Ge\u00e7mi\u015f performansa bakmak, neler olabilece\u011fini anlamam\u0131za yard\u0131mc\u0131 olur. AGIO, \u00f6nemli olaylar etraf\u0131nda dramatik dalgalanmalar g\u00f6stermi\u015ftir:<\/p> <ul> <li><strong>\u015eubat 2025 4. \u00c7eyrek Kazan\u00e7lar\u0131<\/strong>: Gelir tahminlerini a\u015f\u0131nca hisse %18 y\u00fckseldi<\/li> <li><strong>May\u0131s 2025 Klinik Deneme G\u00fcncellemesi<\/strong>: Kay\u0131t gecikmesi haberiyle %12 d\u00fc\u015ft\u00fc<\/li> <li><strong>Temmuz 2025 2. \u00c7eyrek Sonu\u00e7lar\u0131<\/strong>: Kay\u0131plara ra\u011fmen %45 gelir art\u0131\u015f\u0131yla %8 y\u00fckseldi<\/li> <li><strong>Mart 2025 FDA Kabul\u00fc<\/strong>: D\u00fczenleyici ilerleme ile %22 s\u0131\u00e7rama yapt\u0131<\/li> <li><strong>Kas\u0131m 2024 Pipeline Geni\u015flemesi<\/strong>: Yeni ila\u00e7 aday\u0131 ile %15 kazan\u00e7 sa\u011flad\u0131<\/li> <li><strong>A\u011fustos 2024 Ortakl\u0131k Duyurusu<\/strong>: Sahiplik seyrelmesi endi\u015feleriyle %9 d\u00fc\u015ft\u00fc<\/li> <\/ul> <p>Desen a\u00e7\u0131k: olumlu d\u00fczenleyici haberler b\u00fcy\u00fck kazan\u00e7lar getirirken, klinik aksakl\u0131klar keskin d\u00fc\u015f\u00fc\u015flere neden oluyor. Bu volatilite, biyoteknoloji hisselerinin hem riski hem de f\u0131rsat\u0131d\u0131r.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Performans Analizi (Mart-A\u011fustos 2025)<\/h2> <p>AGIO bu y\u0131l olduk\u00e7a ini\u015f \u00e7\u0131k\u0131\u015fl\u0131 bir seyir izledi:<\/p> <ul> <li><strong>Mart 2025<\/strong>: 32,50 $ - FDA kabul\u00fcnden sonra g\u00fc\u00e7l\u00fc ba\u015flang\u0131\u00e7<\/li> <li><strong>Nisan 2025<\/strong>: 41,80 $ - Kazan\u00e7lar \u00f6ncesi en y\u00fcksek iyimserlik<\/li> <li><strong>May\u0131s 2025<\/strong>: 35,20 $ - Deneme endi\u015feleriyle geri \u00e7ekilme<\/li> <li><strong>Haziran 2025<\/strong>: 38,90 $ - Pozitif verilerle toparlanma<\/li> <li><strong>Temmuz 2025<\/strong>: 36,40 $ - Kar\u0131\u015f\u0131k 2. \u00e7eyrek tepkisi<\/li> <li><strong>A\u011fustos 2025<\/strong>: 37,01 $ - Mevcut konsolidasyon<\/li> <\/ul> <p>Hisse bu d\u00f6nemde <strong>%14 genel b\u00fcy\u00fcme<\/strong> g\u00f6sterdi ancak ay i\u00e7i %20+ kalp durduran dalgalanmalar ya\u015fad\u0131. Bu, cesaret isteyen klasik biyoteknoloji davran\u0131\u015f\u0131d\u0131r; sab\u0131r b\u00fcy\u00fck \u00f6d\u00fcller (ya da cezalar) getirebilir.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut kataliz\u00f6rler ve pipeline potansiyeline dayanarak analistler \u015fu projeksiyonlar\u0131 yap\u0131yor:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 42-48 $ aral\u0131\u011f\u0131 (%15-30 y\u00fckseli\u015f) - FDA onay\u0131 halinde <strong>AL<\/strong> tavsiyesi<\/li> <li><strong>2026 Hedefi<\/strong>: 55-65 $ (%50-75 b\u00fcy\u00fcme) - Orak h\u00fccre denemesinin ba\u015far\u0131s\u0131na ba\u011fl\u0131<\/li> <li><strong>2028 Projeksiyonu<\/strong>: 75-90 $ - Birden fazla onaylanm\u0131\u015f endikasyon<\/li> <li><strong>2030 Vizyonu<\/strong>: 100 $+ - Metabolik bozukluklarda pazar liderli\u011fi<\/li> <\/ul> <p>Ana fark yaratan? <strong>7 Eyl\u00fcl FDA karar\u0131<\/strong>. Onay, hisseyi 50 $+ seviyelerine f\u0131rlatabilirken, reddedilme 25-30 $ seviyelerine geri \u00e7ekebilir.<\/p> <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Neler Yanl\u0131\u015f Gidebilir?<\/h2> <h3>Ba\u015fl\u0131ca Riskler<\/h3> <ul> <li><strong>FDA Reddetme Riski<\/strong>: Sekt\u00f6r ortalamalar\u0131na g\u00f6re %40 tam yan\u0131t mektubu ihtimali<\/li> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: 2025 sonu beklenen Faz 3 orak h\u00fccre verileri hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratabilir<\/li> <li><strong>Nakit Yakma Endi\u015feleri<\/strong>: Gelir art\u0131\u015f\u0131na ra\u011fmen \u00e7eyreklik 112 milyon $ zarar<\/li> <li><strong>Rekabet<\/strong>: Nadir hastal\u0131k alan\u0131na giren b\u00fcy\u00fck ila\u00e7 firmalar\u0131<\/li> <li><strong>Piyasa Volatilitesi<\/strong>: 52 haftal\u0131k 23,41 $-62,58 $ aral\u0131\u011f\u0131 a\u015f\u0131r\u0131 dalgalanmalar g\u00f6steriyor<\/li> <\/ul> <h3>2025 \u0130\u00e7in Olumlu Sinyaller<\/h3> <ul> <li><strong>%45 Gelir Art\u0131\u015f\u0131<\/strong>: PYRUKYND sat\u0131\u015flar\u0131 anlaml\u0131 \u015fekilde h\u0131zlan\u0131yor<\/li> <li><strong>1,3 Milyar $ Nakit Yast\u0131\u011f\u0131<\/strong>: Birden fazla klinik sonu\u00e7 aras\u0131nda finansal dayan\u0131kl\u0131l\u0131k<\/li> <li><strong>\u00c7oklu Kataliz\u00f6rler<\/strong>: FDA karar\u0131 + deneme sonu\u00e7lar\u0131 = potansiyel \u00e7ift kazan\u00e7<\/li> <li><strong>Nadir Hastal\u0131k Odakl\u0131l\u0131k<\/strong>: Ana ak\u0131m piyasalara g\u00f6re daha az rekabet\u00e7i<\/li> <li><strong>K\u00fcresel Geni\u015fleme<\/strong>: Suudi onay\u0131 uluslararas\u0131 potansiyeli g\u00f6steriyor<\/li> <\/ul> <h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>FDA Karar\u0131n\u0131 Bekleyin<\/strong>: 7 Eyl\u00fcl \u00e7ok ikili bir tarih, risk almadan kenardan izleyin<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131 Yap\u0131n<\/strong>: Al\u0131m yap\u0131yorsan\u0131z, zamanlama riskini azaltmak i\u00e7in k\u00fc\u00e7\u00fck haftal\u0131k al\u0131mlar kullan\u0131n<\/li> <li><strong>Stop-Loss Belirleyin<\/strong>: Volatilite g\u00f6z \u00f6n\u00fcne al\u0131narak maksimum %15 zarar korumas\u0131<\/li> <li><strong>\u00c7e\u015fitlendirin<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn tek bir biyoteknolojiye %5'ten fazlas\u0131n\u0131 ay\u0131rmay\u0131n<\/li> <\/ol> <p>Esprili deneyimli tavsiye: \"AGIO ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. Koruyucu g\u00f6zl\u00fcklerinizi tak\u0131n ve t\u00fcm servetinizi tek bir deneyde riske atmay\u0131n!\"<\/p> <h2>\u2705 Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve d\u00fc\u015f\u00fck komisyon oranlar\u0131 sa\u011flay\u0131n<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Risk uygun sermaye ile ba\u015flay\u0131n (\u00f6nerilen 500-1000 $)<\/td><\/tr> <tr><td>3<\/td><td>G\u00fcncel De\u011feri Ara\u015ft\u0131r\u0131n<\/td><td>PDUFA tarih durumu ve son haberleri kontrol edin<\/td><\/tr> <tr><td>4<\/td><td>Limit Emri Verin<\/td><td>Fazla \u00f6deme yapmamak i\u00e7in maksimum fiyat\u0131 38 $ olarak belirleyin<\/td><\/tr> <tr><td>5<\/td><td>Pozisyonu \u0130zleyin<\/td><td>Ana seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun (30 $ destek, 45 $ diren\u00e7)<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2> <p>Agios Pharmaceuticals ile ilgilenen ancak volatiliteden \u00e7ekinenler i\u00e7in Pocket Option benzersiz avantajlar sunar:<\/p> <ul> <li><strong>5 $ Minimum Para Yat\u0131rma<\/strong>: B\u00fcy\u00fck taahh\u00fct olmadan biyoteknoloji sular\u0131n\u0131 test etmek i\u00e7in ideal<\/li> <li><strong>An\u0131nda Do\u011frulama<\/strong>: Tek belge KYC ile FDA haberleri etraf\u0131nda hemen i\u015flem yapabilirsiniz<\/li> <li><strong>Esnek Para \u00c7ekme<\/strong>: Kripto dahil 100'den fazla y\u00f6ntemle h\u0131zl\u0131 kar alma<\/li> <li><strong>Risk Y\u00f6netim Ara\u00e7lar\u0131<\/strong>: Volatil hisseler i\u00e7in yerle\u015fik stop loss ve kar al<\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, biyoteknoloji hisseleriyle deneme yapmay\u0131 ve ard\u0131ndan geleneksel arac\u0131 kurumlara daha b\u00fcy\u00fck yat\u0131r\u0131mlar yapmay\u0131 ideal k\u0131lar.<\/p> <h2>\ud83e\uddec 2025'te Agios Pharmaceuticals: \u0130novasyon Lideri<\/h2> <p>Agios, h\u00fccresel metabolizma ara\u015ft\u0131rmalar\u0131nda \u00f6nc\u00fc olup, nadir kan hastal\u0131klar\u0131 i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler geli\u015ftiriyor. PYRUKYND, pir\u00fcvat kinaz eksikli\u011fi olan hastalara yard\u0131mc\u0131 olurken, \u015firketin pipeline'\u0131 talasemi, orak h\u00fccre hastal\u0131\u011f\u0131 ve polisitemi vera gibi milyonlarca ki\u015fiyi etkileyen hastal\u0131klar\u0131 hedefliyor.<\/p> <p>\u015eirketin <a href=\"https:\/\/www.agios.com\/pipeline\/\">benzersiz bilimsel yakla\u015f\u0131m\u0131<\/a>, metabolik yollar \u00fczerine odaklanarak geleneksel ila\u00e7 firmalar\u0131ndan ayr\u0131l\u0131yor. 1,3 milyar dolarl\u0131k nakit rezervi, birden fazla klinik sonu\u00e7 aras\u0131nda finansal dayan\u0131kl\u0131l\u0131k sa\u011flarken, yakla\u015fan FDA karar\u0131 ticari beklentilerini bir gecede de\u011fi\u015ftirebilir.<\/p> <p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025'te Agios ara\u015ft\u0131rmac\u0131lar\u0131, metabolik terapi yakla\u015f\u0131mlar\u0131n\u0131n kan hastal\u0131klar\u0131n\u0131n \u00f6tesinde uygulamalara sahip olabilece\u011fini ke\u015ffettiler\u2014bu da pazar f\u0131rsatlar\u0131n\u0131 birka\u00e7 kat art\u0131rabilecek tamamen yeni tedavi kategorilerinin kap\u0131s\u0131n\u0131 a\u00e7abilir.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 AGIO Hisse Senedi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>31 A\u011fustos 2025 itibar\u0131yla, Agios Pharmaceuticals (AGIO) NASDAQ&#8217;ta <strong>37,01 $<\/strong> seviyesinde i\u015flem g\u00f6rmektedir. Ancak as\u0131l \u00f6nemli olan \u015fu\u2014<strong>7 Eyl\u00fcl 2025<\/strong> bu hisse i\u00e7in kritik g\u00fcn. FDA&#8217;n\u0131n talasemi tedavisi i\u00e7in PYRUKYND onay\u0131n\u0131 verip vermeyece\u011fine karar verece\u011fi tarih, potansiyel olarak 1,2 milyar dolarl\u0131k bir pazar f\u0131rsat\u0131n\u0131 a\u00e7abilir.<\/p>\n<h3>B\u00fcy\u00fck Haberlerin Tarihsel Fiyat Tepkileri<\/h3>\n<p>Ge\u00e7mi\u015f performansa bakmak, neler olabilece\u011fini anlamam\u0131za yard\u0131mc\u0131 olur. AGIO, \u00f6nemli olaylar etraf\u0131nda dramatik dalgalanmalar g\u00f6stermi\u015ftir:<\/p>\n<ul>\n<li><strong>\u015eubat 2025 4. \u00c7eyrek Kazan\u00e7lar\u0131<\/strong>: Gelir tahminlerini a\u015f\u0131nca hisse %18 y\u00fckseldi<\/li>\n<li><strong>May\u0131s 2025 Klinik Deneme G\u00fcncellemesi<\/strong>: Kay\u0131t gecikmesi haberiyle %12 d\u00fc\u015ft\u00fc<\/li>\n<li><strong>Temmuz 2025 2. \u00c7eyrek Sonu\u00e7lar\u0131<\/strong>: Kay\u0131plara ra\u011fmen %45 gelir art\u0131\u015f\u0131yla %8 y\u00fckseldi<\/li>\n<li><strong>Mart 2025 FDA Kabul\u00fc<\/strong>: D\u00fczenleyici ilerleme ile %22 s\u0131\u00e7rama yapt\u0131<\/li>\n<li><strong>Kas\u0131m 2024 Pipeline Geni\u015flemesi<\/strong>: Yeni ila\u00e7 aday\u0131 ile %15 kazan\u00e7 sa\u011flad\u0131<\/li>\n<li><strong>A\u011fustos 2024 Ortakl\u0131k Duyurusu<\/strong>: Sahiplik seyrelmesi endi\u015feleriyle %9 d\u00fc\u015ft\u00fc<\/li>\n<\/ul>\n<p>Desen a\u00e7\u0131k: olumlu d\u00fczenleyici haberler b\u00fcy\u00fck kazan\u00e7lar getirirken, klinik aksakl\u0131klar keskin d\u00fc\u015f\u00fc\u015flere neden oluyor. Bu volatilite, biyoteknoloji hisselerinin hem riski hem de f\u0131rsat\u0131d\u0131r.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Performans Analizi (Mart-A\u011fustos 2025)<\/h2>\n<p>AGIO bu y\u0131l olduk\u00e7a ini\u015f \u00e7\u0131k\u0131\u015fl\u0131 bir seyir izledi:<\/p>\n<ul>\n<li><strong>Mart 2025<\/strong>: 32,50 $ &#8211; FDA kabul\u00fcnden sonra g\u00fc\u00e7l\u00fc ba\u015flang\u0131\u00e7<\/li>\n<li><strong>Nisan 2025<\/strong>: 41,80 $ &#8211; Kazan\u00e7lar \u00f6ncesi en y\u00fcksek iyimserlik<\/li>\n<li><strong>May\u0131s 2025<\/strong>: 35,20 $ &#8211; Deneme endi\u015feleriyle geri \u00e7ekilme<\/li>\n<li><strong>Haziran 2025<\/strong>: 38,90 $ &#8211; Pozitif verilerle toparlanma<\/li>\n<li><strong>Temmuz 2025<\/strong>: 36,40 $ &#8211; Kar\u0131\u015f\u0131k 2. \u00e7eyrek tepkisi<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: 37,01 $ &#8211; Mevcut konsolidasyon<\/li>\n<\/ul>\n<p>Hisse bu d\u00f6nemde <strong>%14 genel b\u00fcy\u00fcme<\/strong> g\u00f6sterdi ancak ay i\u00e7i %20+ kalp durduran dalgalanmalar ya\u015fad\u0131. Bu, cesaret isteyen klasik biyoteknoloji davran\u0131\u015f\u0131d\u0131r; sab\u0131r b\u00fcy\u00fck \u00f6d\u00fcller (ya da cezalar) getirebilir.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut kataliz\u00f6rler ve pipeline potansiyeline dayanarak analistler \u015fu projeksiyonlar\u0131 yap\u0131yor:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 42-48 $ aral\u0131\u011f\u0131 (%15-30 y\u00fckseli\u015f) &#8211; FDA onay\u0131 halinde <strong>AL<\/strong> tavsiyesi<\/li>\n<li><strong>2026 Hedefi<\/strong>: 55-65 $ (%50-75 b\u00fcy\u00fcme) &#8211; Orak h\u00fccre denemesinin ba\u015far\u0131s\u0131na ba\u011fl\u0131<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: 75-90 $ &#8211; Birden fazla onaylanm\u0131\u015f endikasyon<\/li>\n<li><strong>2030 Vizyonu<\/strong>: 100 $+ &#8211; Metabolik bozukluklarda pazar liderli\u011fi<\/li>\n<\/ul>\n<p>Ana fark yaratan? <strong>7 Eyl\u00fcl FDA karar\u0131<\/strong>. Onay, hisseyi 50 $+ seviyelerine f\u0131rlatabilirken, reddedilme 25-30 $ seviyelerine geri \u00e7ekebilir.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Neler Yanl\u0131\u015f Gidebilir?<\/h2>\n<h3>Ba\u015fl\u0131ca Riskler<\/h3>\n<ul>\n<li><strong>FDA Reddetme Riski<\/strong>: Sekt\u00f6r ortalamalar\u0131na g\u00f6re %40 tam yan\u0131t mektubu ihtimali<\/li>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: 2025 sonu beklenen Faz 3 orak h\u00fccre verileri hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratabilir<\/li>\n<li><strong>Nakit Yakma Endi\u015feleri<\/strong>: Gelir art\u0131\u015f\u0131na ra\u011fmen \u00e7eyreklik 112 milyon $ zarar<\/li>\n<li><strong>Rekabet<\/strong>: Nadir hastal\u0131k alan\u0131na giren b\u00fcy\u00fck ila\u00e7 firmalar\u0131<\/li>\n<li><strong>Piyasa Volatilitesi<\/strong>: 52 haftal\u0131k 23,41 $-62,58 $ aral\u0131\u011f\u0131 a\u015f\u0131r\u0131 dalgalanmalar g\u00f6steriyor<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Olumlu Sinyaller<\/h3>\n<ul>\n<li><strong>%45 Gelir Art\u0131\u015f\u0131<\/strong>: PYRUKYND sat\u0131\u015flar\u0131 anlaml\u0131 \u015fekilde h\u0131zlan\u0131yor<\/li>\n<li><strong>1,3 Milyar $ Nakit Yast\u0131\u011f\u0131<\/strong>: Birden fazla klinik sonu\u00e7 aras\u0131nda finansal dayan\u0131kl\u0131l\u0131k<\/li>\n<li><strong>\u00c7oklu Kataliz\u00f6rler<\/strong>: FDA karar\u0131 + deneme sonu\u00e7lar\u0131 = potansiyel \u00e7ift kazan\u00e7<\/li>\n<li><strong>Nadir Hastal\u0131k Odakl\u0131l\u0131k<\/strong>: Ana ak\u0131m piyasalara g\u00f6re daha az rekabet\u00e7i<\/li>\n<li><strong>K\u00fcresel Geni\u015fleme<\/strong>: Suudi onay\u0131 uluslararas\u0131 potansiyeli g\u00f6steriyor<\/li>\n<\/ul>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>FDA Karar\u0131n\u0131 Bekleyin<\/strong>: 7 Eyl\u00fcl \u00e7ok ikili bir tarih, risk almadan kenardan izleyin<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131 Yap\u0131n<\/strong>: Al\u0131m yap\u0131yorsan\u0131z, zamanlama riskini azaltmak i\u00e7in k\u00fc\u00e7\u00fck haftal\u0131k al\u0131mlar kullan\u0131n<\/li>\n<li><strong>Stop-Loss Belirleyin<\/strong>: Volatilite g\u00f6z \u00f6n\u00fcne al\u0131narak maksimum %15 zarar korumas\u0131<\/li>\n<li><strong>\u00c7e\u015fitlendirin<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn tek bir biyoteknolojiye %5&#8217;ten fazlas\u0131n\u0131 ay\u0131rmay\u0131n<\/li>\n<\/ol>\n<p>Esprili deneyimli tavsiye: &#8220;AGIO ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. Koruyucu g\u00f6zl\u00fcklerinizi tak\u0131n ve t\u00fcm servetinizi tek bir deneyde riske atmay\u0131n!&#8221;<\/p>\n<h2>\u2705 Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve d\u00fc\u015f\u00fck komisyon oranlar\u0131 sa\u011flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Risk uygun sermaye ile ba\u015flay\u0131n (\u00f6nerilen 500-1000 $)<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>G\u00fcncel De\u011feri Ara\u015ft\u0131r\u0131n<\/td>\n<td>PDUFA tarih durumu ve son haberleri kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limit Emri Verin<\/td>\n<td>Fazla \u00f6deme yapmamak i\u00e7in maksimum fiyat\u0131 38 $ olarak belirleyin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Pozisyonu \u0130zleyin<\/td>\n<td>Ana seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun (30 $ destek, 45 $ diren\u00e7)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2>\n<p>Agios Pharmaceuticals ile ilgilenen ancak volatiliteden \u00e7ekinenler i\u00e7in Pocket Option benzersiz avantajlar sunar:<\/p>\n<ul>\n<li><strong>5 $ Minimum Para Yat\u0131rma<\/strong>: B\u00fcy\u00fck taahh\u00fct olmadan biyoteknoloji sular\u0131n\u0131 test etmek i\u00e7in ideal<\/li>\n<li><strong>An\u0131nda Do\u011frulama<\/strong>: Tek belge KYC ile FDA haberleri etraf\u0131nda hemen i\u015flem yapabilirsiniz<\/li>\n<li><strong>Esnek Para \u00c7ekme<\/strong>: Kripto dahil 100&#8217;den fazla y\u00f6ntemle h\u0131zl\u0131 kar alma<\/li>\n<li><strong>Risk Y\u00f6netim Ara\u00e7lar\u0131<\/strong>: Volatil hisseler i\u00e7in yerle\u015fik stop loss ve kar al<\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, biyoteknoloji hisseleriyle deneme yapmay\u0131 ve ard\u0131ndan geleneksel arac\u0131 kurumlara daha b\u00fcy\u00fck yat\u0131r\u0131mlar yapmay\u0131 ideal k\u0131lar.<\/p>\n<h2>\ud83e\uddec 2025&#8217;te Agios Pharmaceuticals: \u0130novasyon Lideri<\/h2>\n<p>Agios, h\u00fccresel metabolizma ara\u015ft\u0131rmalar\u0131nda \u00f6nc\u00fc olup, nadir kan hastal\u0131klar\u0131 i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler geli\u015ftiriyor. PYRUKYND, pir\u00fcvat kinaz eksikli\u011fi olan hastalara yard\u0131mc\u0131 olurken, \u015firketin pipeline&#8217;\u0131 talasemi, orak h\u00fccre hastal\u0131\u011f\u0131 ve polisitemi vera gibi milyonlarca ki\u015fiyi etkileyen hastal\u0131klar\u0131 hedefliyor.<\/p>\n<p>\u015eirketin <a href=\"https:\/\/www.agios.com\/pipeline\/\">benzersiz bilimsel yakla\u015f\u0131m\u0131<\/a>, metabolik yollar \u00fczerine odaklanarak geleneksel ila\u00e7 firmalar\u0131ndan ayr\u0131l\u0131yor. 1,3 milyar dolarl\u0131k nakit rezervi, birden fazla klinik sonu\u00e7 aras\u0131nda finansal dayan\u0131kl\u0131l\u0131k sa\u011flarken, yakla\u015fan FDA karar\u0131 ticari beklentilerini bir gecede de\u011fi\u015ftirebilir.<\/p>\n<p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025&#8217;te Agios ara\u015ft\u0131rmac\u0131lar\u0131, metabolik terapi yakla\u015f\u0131mlar\u0131n\u0131n kan hastal\u0131klar\u0131n\u0131n \u00f6tesinde uygulamalara sahip olabilece\u011fini ke\u015ffettiler\u2014bu da pazar f\u0131rsatlar\u0131n\u0131 birka\u00e7 kat art\u0131rabilecek tamamen yeni tedavi kategorilerinin kap\u0131s\u0131n\u0131 a\u00e7abilir.<\/p>\n"},"faq":[{"question":"Agios Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, g\u00fcncel de\u011ferlemeyi ara\u015ft\u0131r\u0131n, limit emri verin ve pozisyonunuzu izleyin."},{"question":"AGIO hisselerinin riskleri nelerdir?","answer":"FDA reddi, klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, nakit yakma, rekabet ve y\u00fcksek piyasa volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"FDA karar\u0131 AGIO hisselerini nas\u0131l etkiler?","answer":"Onay hisseyi 50 $+ seviyelerine \u00e7\u0131karabilir, reddedilme ise 25-30 $ seviyelerine d\u00fc\u015f\u00fcrebilir."},{"question":"Yeni ba\u015flayanlar AGIO hisseleri i\u00e7in ne yapmal\u0131?","answer":"FDA karar\u0131n\u0131 beklemek, dolar maliyet ortalamas\u0131 yapmak, stop-loss belirlemek ve portf\u00f6y\u00fc \u00e7e\u015fitlendirmek \u00f6nerilir."},{"question":"Pocket Option biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, an\u0131nda do\u011frulama, esnek para \u00e7ekme ve risk y\u00f6netim ara\u00e7lar\u0131 sunar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Agios Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, g\u00fcncel de\u011ferlemeyi ara\u015ft\u0131r\u0131n, limit emri verin ve pozisyonunuzu izleyin."},{"question":"AGIO hisselerinin riskleri nelerdir?","answer":"FDA reddi, klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, nakit yakma, rekabet ve y\u00fcksek piyasa volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"FDA karar\u0131 AGIO hisselerini nas\u0131l etkiler?","answer":"Onay hisseyi 50 $+ seviyelerine \u00e7\u0131karabilir, reddedilme ise 25-30 $ seviyelerine d\u00fc\u015f\u00fcrebilir."},{"question":"Yeni ba\u015flayanlar AGIO hisseleri i\u00e7in ne yapmal\u0131?","answer":"FDA karar\u0131n\u0131 beklemek, dolar maliyet ortalamas\u0131 yapmak, stop-loss belirlemek ve portf\u00f6y\u00fc \u00e7e\u015fitlendirmek \u00f6nerilir."},{"question":"Pocket Option biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, an\u0131nda do\u011frulama, esnek para \u00e7ekme ve risk y\u00f6netim ara\u00e7lar\u0131 sunar."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Agios Pharmaceuticals, Inc. (AGIO) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Agios Pharmaceuticals, Inc. (AGIO) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-31T11:46:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-31T11:46:31+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Agios Pharmaceuticals, Inc. (AGIO) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-31T11:46:30+00:00\",\"dateModified\":\"2025-08-31T11:46:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/\",\"name\":\"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Agios Pharmaceuticals, Inc. (AGIO) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"datePublished\":\"2025-08-31T11:46:30+00:00\",\"dateModified\":\"2025-08-31T11:46:31+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Agios Pharmaceuticals, Inc. (AGIO) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Agios Pharmaceuticals, Inc. (AGIO) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/","og_locale":"tr_TR","og_type":"article","og_title":"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Agios Pharmaceuticals, Inc. (AGIO) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-31T11:46:30+00:00","article_modified_time":"2025-08-31T11:46:31+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Agios Pharmaceuticals, Inc. (AGIO) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-31T11:46:30+00:00","dateModified":"2025-08-31T11:46:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/","name":"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Agios Pharmaceuticals, Inc. (AGIO) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","datePublished":"2025-08-31T11:46:30+00:00","dateModified":"2025-08-31T11:46:31+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Agios Pharmaceuticals, Inc. (AGIO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Agios Pharmaceuticals, Inc. (AGIO) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":364086,"slug":"how-to-buy-agios-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Agios Pharmaceuticals, Inc. (AGIO) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Agios Pharmaceuticals, Inc. (AGIO)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":364085,"slug":"how-to-buy-agios-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Agios Pharmaceuticals, Inc. (AGIO) - Investimento em a\u00e7\u00f5es da Agios Pharmaceuticals, Inc. (AGIO)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-agios-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/364087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=364087"}],"version-history":[{"count":1,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/364087\/revisions"}],"predecessor-version":[{"id":364089,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/364087\/revisions\/364089"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334027"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=364087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=364087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=364087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}